In 2014, public health advocates in Colombia asked the government to issue a compulsory license on imatinib, an expensive leukemia drug marketed there by Novartis at a price almost twice the Colombian per capita income.

The Colombian Minister of Health, Alejandro Gaviria, indicated in April 2016 that he would declare a compulsory license to be in the public interest, one of the steps in issuing a compulsory license in Colombia.

Knowledge Ecology International leaked documents in May 2016 after news reports indicated that the U.S. Senate Finance Committee and U.S. Trade Representative were pressuring the Colombian government to not grant the compulsory license.

Below are links to other blogs and reports involving Colombia.

More detailed background is here.

James Love and Andrew S. Goldman. Colombia Asked To Declare Excessive Price For Cancer Drug Contrary To Public Interest, Grounds For Compulsory License. IP-Watch. December 3, 2015.

Novartis sales of Gleevec/Glivec (INN: Imatinib), 2002 to 2016:Q1. Table here in html, xlsx.